Loading...
Market
What will be the ORR for BDTX-1535 in Phase 3 trials by December 31, 2025?
3
Resolution / Starting Odds
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Black Diamond Therapeutics' official Phase 3 trial results and publications
Story
Black Diamond Therapeutics Announces Initial Phase 2 Data for BDTX-1535 in Recurrent NSCLC with 42% ORR at 200 mg
Sep 23, 2024, 11:02 AM
Black Diamond Therapeutics has announced the initial Phase 2 data for its BDTX-1535 treatment in patients with recurrent EGFRm non-small cell lung cancer (NSCLC). The data, which will be presented in a webcast at today's 8am ET call, demonstrates robust anti-tumor activity. A 200 mg daily dose has been selected for pivotal development, showing a favorable tolerability profile. Preliminary overall response rate (ORR) of 42% was observed in 19 patients with on-target resistance EGFR mutations. The treatment is effective against a broad spectrum of classical, non-classical, and C797S resistance mutations.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Greater than 40% • 25%
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Yes • 50%
No • 50%
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Yes • 50%
No • 50%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%